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http://dx.doi.org/10.1016/j.jds.2012.1Abstract Background/purpose: Ventilator-associated pneumonia (VAP) is one of the most
frequent causes of morbidity and mortality among mechanically ventilated patients in critical
care. Previous meta-analyses demonstrated that oral chlorhexidine (CHX) is beneficial in pre-
venting VAP. Several new studies on oral hygiene as a preventive measure for VAP have been
published. Considering all the currently available evidence together, an updated meta-analysis
was conducted to evaluate the efficacy of oral CHX in preventing VAP.
Materials and methods: A comprehensive literature search was conducted to identify clinical
trials comparing oral hygiene care using CHX with conventional care in terms of the incidence
of VAP. Two reviewers independently assessed each report to confirm that all reports met the
inclusion criteria. The data from each trial were combined using the ManteleHaenszel fixed-
effects model to calculate the pooled relative risk and the corresponding 95% confidence inter-
vals. Funnel plots were used to assess publication bias.of Anesthesiology, Saitama Medical University Hospital, Morohongo 38, Moroyama, Saitama 350-4095,
ed.ac.jp (H. Hoshijima).
iation for Dental Sciences of the Republic of China. Published by Elsevier Taiwan LLC. All rights reserved.
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Oral hygiene and prevention of VAP 349Results: Nine randomized controlled trials met our inclusion criteria. Overall, 1623 patients
received oral hygiene with CHX and 1662 received a placebo. The heterogeneity of the data
was statistically refuted. Oral hygiene using CHX resulted in a reduced incidence of VAP (rela-
tive riskZ 0.59; 95% confidence interval, 0.47e0.73; P< 0.001; I2Z 27.8%) according to a
fixed-effects model. Publication bias was not apparent in the funnel plots.
Conclusion: The analysis showed that oral CHX decontamination significantly reduced the inci-
dence of VAP but not the mortality rate.
Copyright ª 2013, Association for Dental Sciences of the Republic of China. Published by
Elsevier Taiwan LLC. All rights reserved.Introduction
Ventilator-associated pneumonia (VAP) is the most impor-
tant nosocomial infection in critical-care units.1 The inci-
dence of VAP was reported to range 9e27% with a mortality
rate that may exceed 50% for those receiving mechanical
ventilation.24 VAP is associated with a prolonged hospital
stay, increased cost of treatment, and increased morbidity
and mortality rates.5,6 Therefore, prevention of VAP is a
key part of managing patients undergoing mechanical
ventilation.
Several studies investigated the effects of decontami-
nation of the respiratory tract by means of topical chlor-
hexidine (CHX) on the reduction in VAP. The United States
(US) Centers for Disease Control and Prevention (CDC) re-
ported several mechanisms that may be responsible for
VAP, including aspiration of oropharyngeal organisms,
inhalation of aerosols that contain bacteria, hematogenous
spread from distant body sites, and bacterial translocation
from the gastrointestinal tract.7 The most significant
mechanism among those reported is aspiration of oropha-
ryngeal organisms into distal bronchi.
Previous meta-analyses aimed at clarifying the effect of
oral decontamination with CHX yielded conflicting
results.8e11 Results of meta-analyses can be affected by the
methodological diversity of the comparative studies
included, and can change as additional studies are pub-
lished and incorporated. Since the first meta-analysis on
this topic was published in 2006, at least five additional
relevant randomized controlled trial studies have been
published.12e16 In addition, previous meta-analyses
included some methodological variations, precluding the
possibility of a robust conclusion. In this meta-analysis, we
aimed to provide an updated synthesis of the available
evidence regarding the efficacy of oral CHX in preventing
VAP.Materials and methods
A meta-analysis was performed in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-
Analysis guidelines.17 A comprehensive literature search was
performed using MEDLINE, EMBASE, the American College of
Physicians Journal Club database, the Cochrane Database of
Systematic Reviews, the Cochrane Central Register of
Controlled Trials, and theDatabase of Abstracts of Reviews of
Effects. Although the definition of VAP consists of severalcriteria, the widely accepted definition of VAP proposed by
theU.S.CDCwasused.18,19Thesediagnostic criteria includea
fever, cough, and development of sputum, in combination
with radiologic evidence of a new or progressive pulmonary
infiltrate, leukocytosis, a suggestive Gram’s stain, growth of
bacteria in sputum culture, tracheal aspirate, pleural fluid or
blood, and bronchoscopic techniques (e.g., quantitative
culture of protected specimen brush, bronchoalveolar
lavage, and protected bronchoalveolar lavage specimens).
The following text searches and search headings were used,
individually and in combination: chlorhexidine, mechanical
ventilation, oral hygiene,andnosocomial infection.Amanual
search of references listed in reports and reviews was also
performed. Only articles written in English were included.
The date of the most recent search was October 2011.
Two authors (H.H. and R.T.) independently assessed
each article to determine whether it met the inclusion
criteria described below. Disagreements among the authors
regarding values or analysis assignments were resolved
through discussion. To be included in the analysis, each
study had to: be a prospective, randomized trial; compare
topical oropharyngeal CHX with control treatment; involve
ventilator management with tracheal intubation; and
report the incidence of VAP.
Inclusion of data from duplicate publications was care-
fully avoided. Articles from any studies with insufficient
data were not included. An unmasked quality assessment
on the selected published studies was performed by two
investigators using composite aspects of study quality (six
aspects in total, with assigned scores of 0 or 1: randomi-
zation; blindness of outcome measurement; standardized
management of VAP; comparability; withdrawal; and defi-
nition of VAP).20 Differences in opinion were settled by
consensus. Data abstraction was also independently per-
formed by two authors using standardized data-collection
forms. Data extracted from eligible studies included the
following items: patient type; concentration of CHX;
compared drugs; length of the study period in the intensive
care unit (ICU); definition of VAP; reason for tracheal
intubation; and disease severity. Dichotomous data on the
incidence of VAP after oral hygiene using CHX or compared
drugs were also extracted from eligible studies.
Statistical analysis
All statistical analyses were performed using Stata version
SE 11 (StataCorp, College Station, TX, USA). The primary
outcome was the incidence of VAP. A statistical analysis of
350 H. Hoshijima et althe incidence of VAP was performed using the relative risk
(RR), which represents a comparison of the incidence of
VAP in the CHX oral hygiene group with its incidence in the
control group. Statistical significance was indicated by
P< 0.05 if the 95% confidence interval (CI) did not include
the value of 1.0. Because eligible studies exhibited clinical
and methodological diversity, the heterogeneity of the
collected data was assessed using a homogeneity test based
on the c2 test and I2. The I2 statistic was used to assess the
impact of heterogeneity on the results. This statistic in-
dicates the percentage of the variability in effect estimates
that is due to heterogeneity rather than to sampling error.21
Because of the low power of this test, especially when trials
have a small sample size or are few in number, a minimum
cutoff PZ 0.10 and I2Z 50% as the threshold of homoge-
neity was determined to avoid false-negative results;
P< 0.10 and I2> 50% indicated heterogeneity and pre-
vented us from relying on a combination of study results. If
significant homogeneity was statistically denied, then the
ManteleHaenszel fixed-effects model was used to calculate
the pooled RR; otherwise the random-effects model was
used for the combined analysis.
A sensitivity analysis was performed by recalculating the
pooled RR using data from high-quality studies (with a
rating of >5). Subgroup analyses were specified into the
following categories: studies of postcardiac surgery pa-
tients; studies of nonsurgical patients; and studies using
low concentrations of CHX (<0.2%). The effect of oral CHX
on the mortality rate was also analyzed.
Publication bias caused by a tendency not to publish
studies that showed no significant differences can limit the
validity of meta-analysis. To assess the potential for pub-
lication bias, in which RR estimates suggesting strongFigure 1 Meta-analysis flowchart. Rassociations in an expected direction were preferentially
published, a funnel plot was constructed showing the RR
against the associated standard errors.22 An asymmetrical
funnel plot indicated publication bias. Begg’s test was used
to assess the asymmetry of the funnel plot.23
Results
Using electronic databases, 422 articles were initially
identified for review. Of those, 405 studies were excluded
because they were unrelated studies, review articles, or in
the non-English literature. The other 17 articles were
thoroughly checked to determine whether they met our
inclusion criteria. Five studies were excluded because they
did not satisfy the inclusion criteria, and three additional
studies were excluded because the incidence of VAP was
not available, and it was not possible to obtain data from
the respective investigators. In the end, nine stud-
ies12e16,2427 identified by the defined search strategy
satisfied the inclusion criteria in that they contained the
necessary data for the planned comparison. The process by
which eligible studies were identified is depicted in Fig. 1,
and details of the selected trials are summarized in Table 1.
In total, 1623 patients received CHX, while 1662
received a placebo or standard care. The pooled RR was
calculated using the ManteleHaenszel fixed-effects model,
with a result of 0.59 (95% CI, 0.47e0.73; P< 0.001). The
main results of the meta-analysis comparing CHX and con-
trol drugs are summarized in Fig. 2. The test for hetero-
geneity yielded c2 Z 11.08, I2Z 27.8%, and eight degrees
of freedom.
The sensitivity analysis was performed by recalculating
the pooled RR based on higher-quality studies. The pooled RRCTZ randomized controlled trial.
Table 1 Characteristics of included studies.
Ref Year Type of
patients
Concentration
of CHX
Comparator
agent
Definition of ventilator-
associated pneumonia
Reason for tracheal
intubation
Disease severity Length of stay
in ICU (mean,
d)
Study periods Quality
24 1996 Postcardiac
surgery
patients
0.12% Placebo,
same smell
and taste
Infection diagnosis was
based on Centers of Disease
Control and Prevention
criteria
Postcardiac surgery:
CABG, CABG/Valve,
Valve
Not recorded Not recorded Discharge
from ICU or
death
4
25 2000 Nonsurgical
patients
0.20% Isotonic
sodium
bicarbonate
Infection diagnosis was
based on Centers of Disease
Control and Prevention
criteria
Age >18 years, medical
condition suggesting an
ICU stay of 5 d and
requiring mechanical
ventilation by oro- or
nasotracheal intubation
or tracheotomy
SPA II CHX:
37 15 CG:
33 13
CHX: 18 16,
CG: 24 19
ICU stay at
least 5 d,
discharge
from ICU
5
26 2002 Postcardiac
surgery
patients
0.12% Listerine Temperature >38C or
<36C, presence of
infiltrates on chest
radiographs, leukocytosis
(>10 109/L) or
leukocytosis (<3 109/L),
positive culture from
tracheal aspirate and/or
positive culture of blood
cultures and BAL, tracheal
aspirate cultures were
considered positive at 106
CFU/mL, and BAL was
considered positive at 104
CFU/mL
Postcardiac surgery: All
eligible patients who
underwent
aortocoronary bypass
graft and/or valve
surgery requiring
cardiopulmonary bypass
were invited to
participate
Not recorded Not recorded Extubation,
tracheostomy,
death, or
diagnosis
of pneumonia
6
27 2005 Nonsurgical
patients
0.20% Placebo,
same color,
taste, and
smell
Temperature >38C or
<36C, presence of
infiltrates on chest
radiographs, leukocytosis
(>10 109/L) or
leukocytosis (<3 109/L),
positive culture from
tracheal aspirate and/or
positive culture of blood
cultures and BAL, tracheal
aspirate cultures were
considered positive at 106
Acute exacerbation of
chronic obstructive
pulmonary disease
without pneumonia,
acute respiratory
distress syndrome,
community-acquired
pneumonia, central
neurological disease,
intoxication,
polytraumatism,
miscellaneous
SPA II： CHX:
45.2 17.5,
CG: 40.0 17.5
CHX: 14.0 8.5
CG: 13.3 8.8
ICU stay at
least 5 d,
discharge
from ICU,
death
5
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f Year Type of
patients
Concentration
of CHX
Comparator
agent
Definition of ventilator-
associated pneumonia
Reason for tracheal
intubation
Disease severity Length of stay
in ICU (mean,
d)
Study periods Quality
CFU/mL, and BAL was
considered positive at 104
CFU/mL
2006 Postcardiac
surgery
patients
0.12% Placebo,
comparable
color, taste,
and smell
Infection diagnosis was
based on Centers of Disease
Control and Prevention
criteria
Postcardiac surgery:
CABG, valve, combined,
aortic
Not recorded CHX: 1.2 1.1,
CG: 1.3 1.3
Prolonged ICU
stay (>5 d) or
prolonged
mechanical
ventilation
(>48 h)
expected
after surgery
6
2006 Nonsurgical
patients
2.00% Placebo,
same smell
and taste
Presence of infiltrates on
chest radiographs in
combination with at least
three of four criteria: (1)
rectal temperature
>38.0C or <35.5C; (2)
blood leukocytosis
(>10 109/L) and/or left
shift or leukocytosis
(<3 109/L); (3) purulent
aspect of tracheal aspirate;
or (4) a positive
semiquantitive culture
from tracheal aspirates
(cut off 105 CFU/mL)
occurring after 48 h of
mechanical ventilation.
GCS< 8, Respiratory
insufficiency
APACHE II：
CHX:
22.2 7.02,
CG: 21.8 7.43
CHX:
13.37 17.4,
CG:
12.45 12.9
Extubation,
death or
diagnosis of
pneumonia
4
2008 Nonsurgical
patients
2.00% Normal
saline
Presence of infiltrates on
chest radiographs in
combination with at least
three of four criteria:
(1) rectal temperature
>38.0C or <35.5C;
Upper airway
obstruction, oxygenation
failure, airway
protection, secretion
obstruction, ventilator
failure
APACHE II：
CHX:
16.7 7.9, CG:
18.2 8.1
CHX: 7, CG: 21 Extubation 3Ta
Re
12
13
14
(2) blood leukocytosis
(>10 109/L) and/or left
shift or leukocytosis
(<3 109/L); (3) purulent
aspect of tracheal aspirate;
or (4) a positive
semiquantitive culture
from tracheal aspirate
samples that was positive
for pathogenic bacteria.
15 2009 Mixed 0.20% 0.01%
potassium
Presence of infiltrates on
chest radiograph,
temperature >38C,
leukocytosis (12 109/L),
purulent sputum
developing >48 h after
admission to the ICU along
with worsening of
hypoxemia on arterial
blood gas analysis.
Postoperative, APACHE
II, GCS score, aspiration
APACHE II：
CHX: 12 (9e17),
CG: 14 (9e19)
CHX: 5.0 (3.0
e8.0), CG: 6.0
(3.0e8.0)
Discharge
from ICU or
death
6
16 2009 Mixed 0.12% Placebo,
same color,
taste and
smell
Infections diagnosis was
based on Centers of Disease
Control and Prevention
criteria.
Respiratory failure,
compromised mental
status, postoperative
shock
APACHE II：
CHX: 17, CG: 19
CHX: 11.1, CG:
11.0
Discharge
from ICU
6
APACHE IIZ Acute Physiology and Chronic Health Evaluation II; BALZ bronchoalveolar lavage; CABGZ coronary artery bypass grafting; CFUZ colony-forming unit; CGZ control group;
CHXZ chlorhexidine; GCSZGlasgow Coma Scale; ICUZ intensive care unit; MixedZ postcardiac surgery patients and critically-ill patients; SPA IIZ Simplified Acute Physiology Score.
Figure 2 Forest plot of incidence of ventilator-associated pneumonia with chlorhexidine and control groups. The center of each
black diamond represents the relative risks (RR) for individual trials, and the corresponding horizontal line represents the 95%
confidence interval (CI). The open diamond represents the pooled result. dfZ degrees of freedom; RefZ reference.
354 H. Hoshijima et alof 0.64 (95% CI, 0.50e0.82; PZ 0.001; I2Z 40.1%)
was obtained through subgroup analyses of each of the
six studies that had a study quality rating >5
(Table 2).12,15,16,25e27 Furthermore, subgroup analyses were
conducted to explore the effects of known confounding fac-
tors on the incidence of VAP. In three studies, the study
protocol exclusively included postcardiac surgical pa-
tients.12,24,26 Within this subgroup of postcardiac surgical
patients, the pooled RR was 0.47 (95% CI, 0.33e0.65;
PZ 0.0001; I2Z 0.00%). In four studies, the study protocol
included nonsurgical patients.13,14,25,27 In the nonsurgical
patient subgroup, the pooled RRwas 0.59 (95%CI, 0.42e0.86;
PZ 0.006; I2Z 34.9%). Seven studies had varying concen-
trations of CHX (range, 0.12%e0.2%).12,15,16,24e27 In those
studies, the pooled RR was 0.60 (95% CI, 0.47e0.76;
PZ 0.0001; I2Z 43.6%). Data onmortality were available for
all studies. The RR for mortality was 1.14 (95% CI, 0.95e1.35;
PZ 0.13; I2Z 25.1%)12e16,24e27 (Fig. 3).
A funnel plot was used to detect possible publication
bias in the meta-analysis. Begg’s test detected no major
publication bias through a statistical analysis (Kendall’s
scoreZ2.0; Z valueZ0.21; rZ 0.84; Fig. 4). One
article reported a case of temporary minor discoloration of
the teeth associated with CHX.Table 2 Effects of subgroup analysis on meta-analysis compari
Subgroup Refs
High quality studies (score >5) 12,15,16,25e2
Postcardiac surgery patients 12,24,26
Nonsurgical patients 13,14,25,27
Low concentration of CHX (include 0.12%, 0.2%) 12,15,16,24e2
Mortality rate 12e16,24e27
CHXZ chlorhexidine; RRZ relative risk.Discussion
Our analysis showed that oral hygiene using CHX is effective
in preventing VAP. Previous studies reported that the aspi-
ration of oropharyngeal organisms in patients with tracheal
intubations plays a major role in the development of VAP.2
Fourrier et al proved an association between the coloni-
zation of dental plaque by aerobic pathogens, which had
occurred in 46% of patients by Day 10 of their ICU stay, and
the subsequent specific source of the nosocomial infec-
tion.28 Accordingly, attention has since focused on whether
improving oral hygiene can reduce the incidence of VAP.
Several previous studies reported that oral hygiene using
CHX was effective in preventing VAP compared to the use of
a control treatment,12,24,25 but prospective studies
designed specifically to evaluate this point found no sig-
nificant difference between CHX and control groups.15,16,27
Indeed, six of the nine trials that met our inclusion criteria
yielded an RR< 1, indicating that oral hygiene with CHX
does not prevent VAP, whereas only three studies showed a
statistically significant difference.
This meta-analysis represents the largest study to date
regarding the effects of oral CHX antiseptics on preventing
VAP. Since Pineda et al8 published the first meta-analysis onng treatment group and control group.
Pooled RR (95%CI) P Heterogeneity P I2 (%)
7 0.64 (0.50e0.82) 0.001 0.14 40.1
0.47 (0.33e0.65) <0.001 0.71 0.00
0.59 (0.40e0.86) 0.006 0.22 34.9
7 0.60 (0.47e0.76) <0.001 0.11 43.6
1.14 (0.95e1.35) 0.13 0.22 25.1
Figure 3 Forest plot of overall mortality for chlorhexidine and control groups. The center of each black diamond represents the
relative risks (RR) for individual trials, and the corresponding horizontal line represents the 95% confidence interval (CI). The open
diamond represents the pooled result. dfZ degrees of freedom; RefZ reference.
Oral hygiene and prevention of VAP 355this topic in 2006, at least five additional relevant ran-
domized controlled trial studies have been published.12e16
Because a meta-analysis depends on the results of the
included studies, the publication of new studies on
the topic warrants reanalysis of the available evidence. The
2007 meta-analysis by Chlebicki and Safdar9 included re-
sults published as conference abstracts. In our meta-
analysis, however, we excluded one report that was only
delivered as a conference abstract,29 because it would have
been difficult to evaluate whether the results of that study
were relevant to our meta-analysis. Chlebicki and Safdar
also included a study by Grap30 that used a definition of VAP
that differed from ours. Kola and Gastmeier10 conducted a
meta-analysis of seven randomized controlled trials and
concluded that oral decontamination with CHX could pre-
vent VAP in mechanically ventilated patients. Whereas the
Kola and Gastmeier study analyzed studies published up to
2006, we incorporated three additional studies published in
2008 and 2009, in order to update the evidence. Chan
et al11 reached a conclusion similar to ours, as their results
suggested a significant protective effect of oralFigure 4 Funnel plot of the selected trials to explore the
publication bias.decontamination with CHX against VAP, although they
included a trial that had used povidoneeiodine for oral
cleaning. In the interval since the more recent of these
meta-analyses, which was published in 2007, new evidence
evaluating the impact of CHX has been published. Although
our study design differed somewhat from those used in the
previous meta-analyses, our analysis confirmed their find-
ings. Our results strengthen the argument that oral
decontamination with CHX is beneficial in preventing VAP.
The most recent guidelines from the CDC recommend
oral cleaning using CHX (0.12%) during the perioperative
period for adults undergoing cardiac surgery.24 Some pre-
vious studies reported that oral hygiene using CHX does not
reduce the incidence of VAP in postcardiac surgery pa-
tients, but, as Fig. 2 shows, the pooled results of our three
postcardiac surgery studies show a significantly lower inci-
dence of VAP when oral hygiene with CHX was applied. In
nonsurgical patients, however, the question of the effec-
tiveness of oral antiseptic decontamination for preventing
VAP remains unresolved.28 To help clarify this matter, we
analyzed nonsurgical patients as a separate subgroup. Our
results suggested that oral hygiene with CHX is effective at
preventing VAP in nonsurgical patients.
This study revealed that oral cleaning using CHX effec-
tively reduces the incidence of VAP, but the optimal range
of CHX concentrations remains unknown. The varying con-
centrations of CHX used for decontamination in the trials
may have affected our results on the development of VAP.
Koeman et al used a 2.0% solution of CHX that did not
reduce the incidence of nosocomial infection compared to
that seen in control groups,27 but most of the other studies
used much less concentrated solutions of 0.12% or 0.2%.
The most recent studies reported that oral application of a
0.12% solution of CHX was not superior to a placebo for
preventing VAP among ICU patients.15,16 Subgroup analyses
conducted in our meta-analysis showed that the use of
topical CHX at concentrations of 0.12% or 0.2% significantly
prevented the occurrence of VAP. Based on this, we
356 H. Hoshijima et alspeculated that high concentrations of CHX for oral clean-
ing would not provide any additional benefit in terms of VAP
prevention, but may increase the risk of adverse events
such as tooth staining.31
Our analysis failed to find that mortality was reduced
through the use of CHX for oral hygiene; also no previous
meta-analysis on topical CHX9,11 showed a significant
reduction in mortality. The reason for this could be that the
mortality rate was a secondary outcome in most trials,
which would cause the accuracy of the data to be lower
than that of data on a primary outcome; thus pooled ana-
lyses of these data failed to show an effect of oral care
using CHX. Another possible explanation is related to our
inability to distinguish the effect of topical CHX on the
incidence of early- versus late-onset VAP. A previous study
by Bellissimo-Rodrigues et al16 found no difference be-
tween the CHX and control groups in the incidence of res-
piratory tract infections, the total mortality rate, or the
length of the ICU stay, but the time between ICU admission
and onset of the first respiratory tract infection was longer
in the CHX group than in the placebo group. Therefore we
hypothesized that if topical CHX is effective only against
early-onset VAP, its role in mortality related to late-onset
VAP may be marginal. To answer this question, further
clinical trials are needed, using separate data extraction
for the incidences of early- and late-onset VAP.
It should be noted that meta-analysis has some inherent
limitations, in particular, the heterogeneity stemming from
variations in the design of the original studies. Accordingly,
there is some controversy concerning whether the results of
studies with different protocols can justifiably be combined
toward calculating a pooled RR and the establishment of
general conclusions. In addition, variations in patient pop-
ulations, definitions of VAP, and onset time of VAP
contribute to the heterogeneity. These factors can create
significant bias in the results of a study such as the present
one. In addition, since our meta-analysis was based on
published articles, there is also the possibility of a publi-
cation bias. If this study were to be repeated including
unpublished, nonindexed, or non-English articles, different
conclusions could perhaps be reached.32,33
Our analysis suggests that oral hygiene using CHX is
effective in reducing the incidence of VAP in mechanically
ventilated patients. Subgroup analyses revealed that CHX
oral hygiene is effective in both postcardiac and nonsurgical
patients. Most of the previously published studies used
relatively low concentrations of chlorhexidine (0.12e0.2%),
and higher concentrations seem to offer no additional
benefit in terms of VAP prevention. The analysis of currently
available evidence failed to showoverall mortality reduction
resulting from CHX oral hygiene in ICU patients.
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